Compare Stocks

→ Elon Musk’s ChatGPT Could Soon Mint New Millionaires (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABC ABcann Global		C$0.00	C$0.00 ▼ C$0.00	N/A	N/A	N/A	N/A
BTG B2Gold	$2.66 -1.8%	$2.90	$2.34 ▼ $4.29	$3.47B	1.09	11.98 million shs	10.45 million shs
CRON Cronos Group	$2.49 +2.0%	$2.31	$1.64 ▼ $2.99	$951.21M	1.17	2.86 million shs	1.24 million shs
GNS Genius Group	$0.41 +0.2%	$0.00	$0.24 ▼ $2.48	$30.49M	11.91	6.21 million shs	1.26 million shs
TRIL Trillium Therapeutics	$18.44	$18.12	$5.80 ▼ $20.96	$1.94B	2.08	1.87 million shs	8 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BTG B2Gold	0.00%	+1.05%	+10.31%	-3.34%	-32.00%
CRON Cronos Group	-2.79%	-9.63%	+16.19%	+19.61%	+31.18%
GNS Genius Group	0.00%	0.00%	0.00%	0.00%	-80.74%
TRIL Trillium Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%

Elon Musk’s ChatGPT Could Soon Mint New Millionaires (Ad)

Elon Musk made $180 million on PayPal… $47 Billion on SpaceX…and $94.2 Billion on Tesla. He’s about to shock the world again with his version of ChatGPT.

And you could go along for the ride if you make this one simple move.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABC ABcann Global	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
BTG B2Gold	4.1974 of 5 stars	3.3	5.0	1.7	0.0	3.1	1.7	2.5
CRON Cronos Group	1.4832 of 5 stars	2.2	5.0	0.0	0.0	2.6	0.0	1.3
GNS Genius Group	0.4882 of 5 stars	0.0	2.0	0.0	0.0	2.1	1.7	1.3
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABC ABcann Global	N/A	N/A	N/A	N/A
BTG B2Gold	2.60	Moderate Buy	$4.85	82.33% Upside
CRON Cronos Group	2.33	Hold	$2.83	13.79% Upside
GNS Genius Group	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest GNS, TRIL, ABC, CRON, and BTG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/8/2024	CRON Cronos Group	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Underperform ➝ Underperform	$2.00 ➝ $2.50
3/28/2024	BTG B2Gold	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$4.00 ➝ $3.50
2/29/2024	BTG B2Gold	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$3.50
1/25/2024	BTG B2Gold	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$4.20 ➝ $3.60
1/24/2024	BTG B2Gold	CIBC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform	$4.60 ➝ $4.20

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABC ABcann Global	N/A	N/A	N/A	N/A	N/A	N/A
BTG B2Gold	$1.93B	1.79	$0.53 per share	5.02	$3.00 per share	0.89
CRON Cronos Group	$87.24M	10.90	N/A	N/A	$2.87 per share	0.87
GNS Genius Group	$18.19M	1.68	N/A	N/A	$0.50 per share	0.83
TRIL Trillium Therapeutics	$150K	12,907.39	N/A	N/A	$2.56 per share	7.20

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABC ABcann Global	N/A	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
BTG B2Gold	$10.10M	$0.02	133.07	6.49	1.95	0.31%	9.09%	7.54%	5/7/2024 (Estimated)
CRON Cronos Group	-$73.96M	-$0.19	N/A	83.00	N/A	-84.15%	-3.99%	-3.87%	5/14/2024 (Estimated)
GNS Genius Group	-$55.05M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	-$59.35M	$0.62	29.74	N/A	N/A	N/A	-23.31%	-18.66%	N/A

Latest GNS, TRIL, ABC, CRON, and BTG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/29/2024	Q4 2023	CRON Cronos Group	N/A	-$0.05	-$0.05	$0.02	$25.15 million	$23.92 million
2/22/2024	Q4 2023	BTG B2Gold	$0.08	$0.07	-$0.01	$0.23	$512.00 million	$511.97 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABC ABcann Global	N/A	N/A	N/A	N/A	N/A
BTG B2Gold	$0.08	3.01%	+13.30%	400.20%	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
GNS Genius Group	N/A	N/A	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	N/A	N/A	N/A	N/A

Latest GNS, TRIL, ABC, CRON, and BTG Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
2/21/2024	BTG B2Gold	quarterly	$0.04	6.4%	3/6/2024	3/7/2024	3/20/2024

(Data available from 1/1/2013 forward)

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABC ABcann Global	N/A	N/A	N/A
BTG B2Gold	0.04	2.27	1.16
CRON Cronos Group	N/A	22.54	21.81
GNS Genius Group	N/A	N/A	N/A
TRIL Trillium Therapeutics	N/A	19.82	19.82

Ownership

Institutional Ownership

Company	Institutional Ownership
ABC ABcann Global	N/A
BTG B2Gold	61.40%
CRON Cronos Group	8.71%
GNS Genius Group	14.28%
TRIL Trillium Therapeutics	87.15%

Insider Ownership

Company	Insider Ownership
ABC ABcann Global	N/A
BTG B2Gold	1.18%
CRON Cronos Group	1.96%
GNS Genius Group	51.19%
TRIL Trillium Therapeutics	9.10%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ABC ABcann Global	N/A	N/A	N/A	Not Optionable
BTG B2Gold	6,150	1.30 billion	1.29 billion	Not Optionable
CRON Cronos Group	356	382.01 million	374.52 million	Optionable
GNS Genius Group	475	73.87 million	36.06 million	Not Optionable
TRIL Trillium Therapeutics	33	105.00 million	95.44 million	Optionable

GNS, TRIL, ABC, CRON, and BTG Headlines

Source	Headline
	Cachet Bicycle shakes off COVID baytoday.ca - February 25 at 12:23 PM
	Rejuvenate your look with a trip to Fourth Avenue Medical Aesthetics chch.com - January 30 at 5:32 PM
	TTI apprehends motorists for illegal removal of clamps, hunt for four others underway bulawayo24.com - January 30 at 5:32 PM
	BridgeBio raises $1.25bn, and other biotech financings pharmaphorum.com - January 19 at 7:18 AM
	Ratio Therapeutics Raises $50M in Series B Financing precisionmedicineonline.com - January 17 at 1:39 PM
	Leiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.com businesswire.com - November 10 at 1:22 PM
	Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, Predictions benzinga.com - November 8 at 1:30 AM
	The Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast period uk.finance.yahoo.com - July 31 at 9:03 AM
	Ratio Therapeutics unveils new research and development facility biopharma-reporter.com - May 15 at 10:33 AM
	WHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death' msn.com - April 26 at 12:18 AM
	Leukemia Therapeutics Global Market Report 2023 uk.finance.yahoo.com - April 4 at 10:35 AM
	Ratio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with Merck finance.yahoo.com - March 28 at 9:12 AM
	Trillium House, an affordable housing project in Warrenton, close to completion dailyastorian.com - January 10 at 12:26 AM
	FDA Grants Fast Track Designation to Tvardi Therapeutics’ TTI-101 for Hepatocellular Carcinoma nz.finance.yahoo.com - October 19 at 9:39 AM
	Cardiff Oncology: 41% Loss In One Day For A Best-In-Class Colorectal Cancer Treatment seekingalpha.com - September 14 at 9:48 AM
	Zentalis Pharmaceuticals Appoints Dr. Jan Skvarka to its Board of Directors nz.finance.yahoo.com - September 12 at 7:55 AM
	Pfizer: Deal For Global Blood Therapeutics Carries Risk - More M&A Is Needed seekingalpha.com - August 17 at 11:07 AM
	TTI reviews parking model chronicle.co.zw - August 10 at 10:41 PM
	TTI working round the clock to configure its systems chronicle.co.zw - August 10 at 10:41 PM
	Pfizer in advanced talks to buy firm making sickle cell drugs pmnewsnigeria.com - August 7 at 3:57 AM
	10 Psychedelics CEOs To Pay Attention To In 2022 markets.businessinsider.com - June 22 at 10:08 AM
	Highlights from ASCO Annual Meeting 2022 healio.com - June 15 at 1:37 PM
	Chlormethine gel may be more effective than ointment for mycosis fungoides healio.com - May 27 at 4:34 PM
	Pfizer and Moderna created life-saving vaccines. So why are their stocks crumbling? edition.cnn.com - May 20 at 2:06 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

Micron Technology Results Proves AI is Driving Storage Demand
March 26, 2024 7:35 AM
View Micron Technology Results Proves AI is Driving Storage Demand
Micron Is the NVIDIA of Memory Chips: Here’s Why
March 21, 2024 10:15 AM
View Micron Is the NVIDIA of Memory Chips: Here’s Why
Heat Alert: Micron Just Got Named A Must-Own Stock for Q2
April 10, 2024 10:42 AM
View Heat Alert: Micron Just Got Named A Must-Own Stock for Q2
Are We in a Bear Market? Here are the Signs
March 18, 2024 10:59 AM
View Are We in a Bear Market? Here are the Signs
S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?
March 18, 2024 8:38 AM
View S&P 500 Valuations Hit New Highs: Anticipating a Market Pullback?

All Headlines

Company Descriptions

ABcann Global

CVE:ABC

B2Gold

NYSEAMERICAN:BTG

B2Gold Corp. operates as a gold producer company. It operates the Fekola Mine in Mali, the Masbate Mine in the Philippines, and the Otjikoto Mine in Namibia. The company also has an 100% interest in the Gramalote gold project in Colombia; 24% interest in the Calibre Mining Corp.; and approximately 19% interest in BeMetals Corp. In addition, it has a portfolio of other evaluation and exploration assets in Mali and Finland. The company was incorporated in 2006 and is headquartered in Vancouver, Canada.

Cronos Group

NASDAQ:CRON

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Genius Group

NYSEAMERICAN:GNS

Genius Group Limited, through its subsidiaries, provides entrepreneur education system business development tools and management consultancy services to entrepreneurs and entrepreneur resorts. The company operates through two segments, Education and Campus. It develops comprehensive entrepreneurial education curriculum with a full suite of tools for student learning and faculty earning. The company also owns entrepreneur resorts in Bali and South Africa, which run entrepreneur retreats and workshops; and Genius Café, an entrepreneur beach club in Bali, as well as Genius Central, an entrepreneur co-working hub in Singapore. In addition, it offers home childcare and investment education services; operates entrepreneur education campus that provides a range of programs from pre-primary through primary school, secondary school, and vocational college; and provides career-focused on-campus and online programs at the master's, bachelor's and associate degree level, as well as certificate and continuing education programs. The company operates in Europe/the Middle East/Africa, the Asia/Pacific, and North America/South America. Genius Group Limited was founded in 2002 and is headquartered in Singapore.

Trillium Therapeutics

NASDAQ:TRIL

Trillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial